Evernow is a technology company.
Evernow has raised $29.0M across 1 funding round.
Evernow has raised $29.0M in total across 1 funding round.
Evernow has raised $29.0M in total across 1 funding round.
Evernow's investors include Abstract Ventures, Alumni Ventures, Andreessen Horowitz, Angel investor, Jana Messerschmidt, Atomic, Banana Capital, Beringea, Big Idea Ventures, BoxGroup, Coelius Capital, Collide Capital.
Evernow is a San Francisco-based telehealth company founded in 2019 that provides personalized, science-based menopause care to women over 40, addressing symptoms like hot flashes, weight gain, sleep issues, and sexual health through hormonal and non-hormonal therapies, virtual visits, and ongoing membership support.[1][2][5] It serves women navigating perimenopause and menopause—a 10-20 year transition often overlooked in healthcare—via a responsive platform combining expert providers, customized treatment plans, and 24/7 access, now accepting insurance from major providers like BlueCross BlueShield and UnitedHealth.[3][5][6] The company raised $28.5M in Series A funding in 2022, led by NEA, to expand research, product development, and user growth, demonstrating strong momentum in the digital health space.[3]
Evernow was co-founded in 2019 by Alicia Jackson, Ph.D. (CEO)—a scientist with a background in fertility care—and Aaron Gotwalt, driven by Jackson's personal experience with in vitro fertilization and her discovery of the profound gaps in menopause research and treatment.[1][3] Jackson, frustrated by the lack of awareness around perimenopause and menopause (which affects women for up to 20 years), aimed to build a platform rooted in science, women's lived experiences, and innovation to fill these voids.[2][3][4] Early traction impressed investors like NEA, leading to the $28.5M Series A round backed by high-profile advocates including Gwyneth Paltrow, Drew Barrymore, and Abby Wambach, who amplified advocacy for women's health.[3] This funding marked a pivotal moment, enabling hires, research expansion, and scaling of their tech-enabled model.[3]
Evernow stands out in women's health telehealth through these key strengths:
Evernow rides the women's health tech wave, targeting a massive, underserved menopause market—where 2 million U.S. women enter annually, yet 2/3 of those seeking care go untreated and most physicians feel unprepared—amid rising digital health adoption post-COVID.[3][6] Timing is ideal as hormonal health gains traction, with market forces like aging populations, chronic disease risks (e.g., 50% diabetes spike), and VC interest (e.g., NEA's focus on "enormity" of the opportunity) fueling growth.[3][6] It influences the ecosystem by pioneering telehealth for midlife women, inspiring research investment, and shifting norms through advocacy, potentially reducing long-term healthcare burdens like heart disease (women's top killer).[2][6]
Evernow is poised to dominate menopause care by expanding insurance integrations, AI-enhanced personalization, and longitudinal data to predict chronic risks, capitalizing on trends like longevity tech and gender-specific medicine.[5][6] Regulatory tailwinds for telehealth and growing awareness (e.g., via celebrity networks) could drive user acquisition, while partnerships with insurers signal scalability.[3][5] Its influence may evolve into a full women's longevity platform, tackling post-menopause conditions and setting standards for empathetic, tech-driven healthcare—proving that addressing overlooked gaps like menopause can redefine healthier lives for women over 40.[2][4]
Evernow has raised $29.0M across 1 funding round. Most recently, it raised $29.0M Series A in April 2022.